JAGX vs. ACXP, NLSP, GLYC, CYCN, TLPH, ADXN, APRE, GTBP, DWTX, and KPRX
Should you be buying Jaguar Animal Health stock or one of its competitors? The main competitors of Jaguar Animal Health include Acurx Pharmaceuticals (ACXP), NLS Pharmaceutics (NLSP), GlycoMimetics (GLYC), Cyclerion Therapeutics (CYCN), Talphera (TLPH), Addex Therapeutics (ADXN), Aprea Therapeutics (APRE), GT Biopharma (GTBP), Dogwood Therapeutics (DWTX), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.
Jaguar Animal Health vs. Its Competitors
Acurx Pharmaceuticals (NASDAQ:ACXP) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Acurx Pharmaceuticals has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 2 articles in the media. Jaguar Animal Health's average media sentiment score of 0.61 beat Acurx Pharmaceuticals' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the news media.
Acurx Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -343.92%. Jaguar Animal Health's return on equity of -432.91% beat Acurx Pharmaceuticals' return on equity.
Acurx Pharmaceuticals has higher earnings, but lower revenue than Jaguar Animal Health.
Acurx Pharmaceuticals presently has a consensus price target of $8.00, suggesting a potential upside of 1,503.21%. Jaguar Animal Health has a consensus price target of $60.00, suggesting a potential upside of 2,181.37%. Given Jaguar Animal Health's higher probable upside, analysts clearly believe Jaguar Animal Health is more favorable than Acurx Pharmaceuticals.
Summary
Jaguar Animal Health beats Acurx Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
Get Jaguar Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JAGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:JAGX) was last updated on 7/10/2025 by MarketBeat.com Staff
